Lymerix is off the market

April 2002

The Lyme vaccine Lymerix is off the market due to poor sales.

Many factors may have contributed to the low demand. Lymerix is expensive...used in just a few states...and isn't very effective.

It has also gotten a lot of bad press.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Pharmacies are setting up pharmaceutical care centers
Diabetes stronger warnings about Actos and heart failure
Diabetes metformin can lower vitamin B12 levels
Diabetes confused about the "sugar-free" candies marketed to patients with diabetes
Osteoporosis latest thinking on treating osteoporosis in postmenopausal women
Cardiology More patients will be taking Plavix (clopidogrel)
Multiple Sclerosis new interferon for MS called Rebif
Obesity & Weight Loss new concerns about the safety of Meridia (sibutramine)
Obesity & Weight Loss natural weight loss products
nocebo effect
Hematology & Oncology Neulasta (pegfilgrastim), a new long-acting form of Neupogen (filgrastim)
Vaccines Lymerix is off the market
Vaccines current vaccine shortages
Alzheimer Disease link between homocysteine levels and dementia
Practice Claritin will go OTC soon